陳吉寧晤英國阿斯利康全球執行董事兼CEO 稱歡迎加大投資佈局力度
上海市委書記陳吉寧昨日(26日)會見英國阿斯利康全球執行董事兼首席執行官蘇博科時表示,阿斯利康為全球領先的醫藥企業,歡迎把握發展機遇,在既有良好合作基礎上將自身優勢與上海的市場優勢、科創優勢、臨床優勢及人才優勢等更加緊密結合起來,持續加大投資佈局力度,深化創新項目合作對接,努力提供更高質量的醫療健康產品和服務。上海將全力打造市場化、法治化、國際化的一流營商環境,為全球企業及人才團隊在滬深耕發展提供全方位優質服務。(ta/w) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.